Medpace (NASDAQ:MEDP) Issues Earnings Results, Beats Estimates By $0.71 EPS

Medpace (NASDAQ:MEDP) released its quarterly earnings results on Monday. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71, Zacks reports. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace updated its FY 2025 guidance to 11.930-12.690 EPS.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $327.86 on Wednesday. Medpace has a 1 year low of $302.01 and a 1 year high of $459.77. The firm has a 50-day simple moving average of $344.13 and a two-hundred day simple moving average of $349.34. The company has a market cap of $10.19 billion, a P/E ratio of 28.71, a PEG ratio of 1.85 and a beta of 1.36.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MEDP. Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. TD Cowen decreased their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Finally, William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.